Search Within

Heiko Schoder

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (14)
  2. Journal Article (10)
  3. Research Letter (2)
  4. Editorial (1)
Groups
  1. GSK Faculty (27)
  2. Human Oncology and Pathogenesis Program (27)
  3. Molecular Imaging and Therapy Service (27)
  4. Radiology, Department of (27)
  5. Department of Medicine (25)
  6. Sloan Kettering Institute Postdocs (22)

More Groups

People
  1. Santosha Vardhana (17)
  2. Alison Moskowitz (16)
  3. Ariela Noy (15)
  4. Steven Horwitz (15)
  5. Andrew Zelenetz (14)
  6. Anita Kumar (14)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (9)
  4. 2022 (1)
  5. 2021 (4)
  6. 2020 (1)

More Years

Publications
  1. Blood (10)
  2. European Journal of Nuclear Medicine and Molecular Imaging (5)
  3. Hematological Oncology (2)
  4. Journal of Clinical Oncology (2)
  5. Blood Advances (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (11)
  2. Springer (6)
  3. American Society of Clinical Oncology (2)
  4. Wiley Blackwell (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (27)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Prognostic value of [(18)F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies
    Journal Article

    Krebs, S.; Mauguen, A.; Yildirim, O.; Hatzoglou, V.; Francis, J. H.; Schaff, L. R.; Mellinghoff, I. K.; Schòˆder, H.; Grommes, C.
    European Journal of Nuclear Medicine and Molecular Imaging (2021)

    Fulltext@MSK | Save
  • Phase II study of pembrolizumab plus GVD as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Hancock, H.; Davey, T.; Sohail, S.; Santarosa, A.; Pomerantz, L.; Jarjies, C.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Retrospective analysis of gemcitabine and oxaliplatin (GemOx)-based treatment in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
    Meeting Abstract

    Schade, J. R.; Kim, C.; Drill, E.; Qiu, A.; Batlevi, C. L.; Caron, P.; Colbourn, D. S.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Shah, G. L.; Schoder, H.; Hancock, H.; Davey, T.; Joong, C.; Pomerantz, L.; Jarjies, C.; Kumar, A.; Lahoud, O. B.; more...
    Blood (2019)

    Fulltext@MSK | Save
  • Prognostic value of FDG-PET/CT in recurrent/refractory CNS lymphoma receiving Ibrutinib-based therapies
    Meeting Abstract

    Krebs, S.; Wolfe, J.; Mellinghoff, I.; Grommes, C.; Schoder, H.
    European Journal of Nuclear Medicine and Molecular Imaging (2019)

    Fulltext@MSK | Save
  • EGFR and MET amplifications determine response to HER2 inhibition in ERBB2-amplified esophagogastric cancer
    Journal Article

    Sanchez-Vega, F.; Hechtman, J. F.; Castel, P.; Ku, G. Y.; Tuvy, Y.; Won, H.; Fong, C. J.; Bouvier, N.; Nanjangud, G. J.; Soong, J.; more...
    Cancer Discovery (2019)

    Fulltext@MSK | Save
  • Positron emission tomography/computed tomography-based assessments of androgen receptor expression and glycolytic activity as a prognostic biomarker for metastatic castration-resistant prostate cancer
    Journal Article

    Fox, J. J.; Gavane, S. C.; Blanc-Autran, E.; Nehmeh, S.; Gonen, M.; Beattie, B.; Vargas, H. A.; Schoder, H.; Humm, J. L.; Fine, S. W.; more...
    JAMA Oncology (2018)

    Fulltext@MSK | Save